ReproCELL Incorporated
4978.T · Tokyo Stock Exchange · JPY
112,00JPY
+4,00 (+3,70 %)Stand 10. Nov., 6:30
Kennzahlen
- Eröffnung
- 109,00
- Vortag
- 108,00
- Tagesspanne
- 109,00 – 113,00
- 52 Wochen
- 103,00 – 204,00
- Volumen
- 711.800
- Ø Volumen
- 652.811
- Börsenwert
- 11,96 Mrd. ¥
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- 0,6
- Nächste Zahlen
- –
Finanzen
Gerade nicht verfügbar.
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
Gerade nicht verfügbar.
Dividenden und Splits
Gerade nicht verfügbar.
Aktiensplits
Gerade nicht verfügbar.
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
Gerade nicht verfügbar.
Vergleichbare Unternehmen
Gerade nicht verfügbar.
Über das Unternehmen
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.
- CEO
- Chikafumi Yokoyama
- Mitarbeitende
- 101
- Hauptsitz
- Yokohama, JP
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 26. Juni 2013
- Website
- reprocell.com
Nachrichten
Gerade nicht verfügbar.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.